In early 2025, Nigeria's National Health Insurance Authority (NHIA) announced a price cap on insulin: ₦200 per vial, down from a typical market price of ₦5,000–₦8,000. For a patient with type 2 diabetes requiring two vials per month, the savings are substantial—from roughly ₦12,000 to ₦400. But the policy comes with a catch: insulin is only available at designated public health facilities, bypassing the private pharmacies where an estimated 60% of Nigerians with diabetes currently obtain their medication. The cap is a bold step toward affordability, but its design may inadvertently create new barriers for the very people it aims to help.

Nigeria faces a growing diabetes burden. According to the International Diabetes Federation, approximately 3.6 million Nigerians live with diabetes, and many more remain undiagnosed. Type 2 diabetes accounts for over 90% of cases. Insulin is a life-saving treatment for many, yet its cost has long been prohibitive. A vial of insulin typically costs between ₦5,000 and ₦8,000 in private pharmacies, and patients with type 2 diabetes often require two to three vials per month. For a minimum-wage worker earning ₦30,000 per month, insulin alone could consume more than half of their income. The NHIA cap reduces that burden to nearly zero for enrolled patients, but only if they can access a public facility.

How the Policy Works

The NHIA, established under the National Health Insurance Authority Act of 2022, is tasked with ensuring universal health coverage for all Nigerians. The insulin cap is part of a broader effort to make essential medicines affordable. Under the policy, any patient enrolled in NHIA's Basic Health Care Provision Fund (BHCPF) can obtain a monthly supply of insulin for ₦200 per vial at designated primary health centers (PHCs) and some secondary hospitals. The NHIA negotiates bulk procurement prices with manufacturers and distributors, passing the savings directly to patients. However, the dispensing is restricted to public facilities that meet specific storage and handling standards, such as having functional cold chain equipment and trained staff. Private pharmacies, even those that meet these standards, are excluded.

The Access Gap: Rural and Informal-Sector Patients

While the price cap is a victory for affordability, the restriction to public facilities creates a significant access gap. Nigeria's health system is heavily urban-centric: the majority of PHCs are located in cities and towns, leaving rural areas underserved. According to a 2023 report by the National Primary Health Care Development Agency, only about 30% of PHCs have consistent cold chain capacity for insulin storage. In rural states like Yobe, Zamfara, and Ebonyi, patients may need to travel over 50 kilometers to reach a facility that can dispense insulin. For a patient with limited mobility or no access to transportation, the cost of travel and lost wages can outweigh the savings on insulin. Consider the example of Amina, a 45-year-old farmer in a remote village in Katsina State. She earns about ₦15,000 per month from selling vegetables. To reach the nearest PHC with insulin, she must take a two-hour bus ride costing ₦1,500 each way, plus a day of lost income. Her monthly cost for insulin under the cap would be ₦400, but her total cost of access would exceed ₦4,500—still a burden, though less than the pre-cap cost of insulin alone. For many like Amina, the cap is not enough; they need dispensing points closer to home.

Trade-Offs: Safety vs. Access

The NHIA's decision to exclude private pharmacies likely stems from concerns about quality control. Insulin requires proper refrigeration (2–8°C) and careful handling to maintain potency. In Nigeria, the private pharmacy sector is fragmented: some pharmacies have reliable cold chain equipment, but many do not. A 2021 study in Lagos found that only 40% of private pharmacies consistently stored insulin at the correct temperature. To ensure patient safety, the NHIA may have chosen to limit dispensing to facilities it can directly monitor and regulate. However, this trade-off ignores the reality that many patients already rely on private pharmacies, often because public facilities are too far or have stockouts. By excluding private pharmacies, the policy forces patients to switch to a system that may be less convenient and more prone to shortages. Moreover, the NHIA could have adopted a tiered approach: accrediting high-quality private pharmacies that meet cold chain standards, similar to the model used in Kenya.

Lessons from Kenya: Accredited Private Chemists

Kenya faced a similar challenge in 2020 when it introduced a price cap on insulin for its National Hospital Insurance Fund (NHIF) enrollees. Initially, insulin was only available at public hospitals, leading to long queues and poor adherence. In response, the Kenyan Ministry of Health piloted a program to accredit private chemists and pharmacies to dispense capped insulin. The accreditation required proof of functional cold chain, trained staff, and regular reporting. The results were promising: within one year, insulin adherence rates among enrolled patients increased by 30%, and patient satisfaction scores improved significantly. The program also reduced the burden on public hospitals, freeing up resources for other services. Nigeria could adopt a similar approach, leveraging the network of private pharmacies that already serve many diabetes patients. The NHIA could offer incentives for private pharmacies to upgrade their cold chain equipment, such as tax breaks or low-interest loans, while enforcing strict quality standards through regular inspections.

Counter-Argument: Why Restricting to Public Facilities Might Be Justified

Some health policy experts argue that restricting insulin dispensing to public facilities is necessary to maintain equity and prevent fraud. Private pharmacies, they contend, might be tempted to sell capped insulin on the black market at higher prices, undermining the policy's intent. In a country where counterfeit medicines are a known problem, the NHIA may want to keep tight control over the supply chain. Public facilities also provide a setting for comprehensive diabetes care, including blood glucose monitoring, dietary counseling, and foot checks—services that private pharmacies may not offer. For a newly diagnosed patient, receiving insulin at a PHC ensures they are also educated about proper use and side effects. However, this argument assumes that public facilities are adequately stocked and staffed, which is not always the case. Many PHCs suffer from chronic drug shortages and understaffing, leading to long wait times and frustration. A balanced approach would be to allow accredited private pharmacies to dispense insulin while requiring them to refer patients for initial and periodic check-ups at public facilities.

Impact on Different Patient Groups

The policy's impact varies by patient profile. For urban, formal-sector workers who live near a well-functioning PHC, the cap is a windfall. Take Chidi, a 50-year-old accountant in Lagos who earns ₦250,000 per month. He previously spent ₦16,000 per month on insulin. Now he pays ₦400, saving ₦15,600. He can walk to the nearest PHC in 15 minutes. For him, the policy is transformative. But for rural, informal-sector workers like Fatima, a 55-year-old trader in Kano State who earns ₦20,000 per month, the savings are offset by travel costs and lost income. She previously bought insulin from a local pharmacy at ₦6,000 per vial. Now she must travel 30 kilometers to a PHC, costing ₦1,000 for transport and a day's wages. Her total cost drops from ₦12,000 to ₦2,400, but the inconvenience may cause her to skip refills. For patients with type 1 diabetes, who require insulin for survival, any barrier to access can be life-threatening. A missed dose due to distance or stockout can lead to diabetic ketoacidosis, a costly emergency. The policy must ensure that the most vulnerable patients are not left behind.

Data Gaps and Monitoring Needs

To evaluate the policy's effectiveness, the NHIA needs robust data on patient outcomes. Currently, there is limited publicly available data on how many patients have accessed capped insulin, their adherence rates, or their glycemic control. The NHIA should invest in a digital tracking system that records dispensing at each facility, patient follow-up visits, and clinical outcomes. Such data can help identify facilities with low uptake or high dropout rates, enabling targeted interventions. For example, if a PHC in a rural area dispenses insulin to only 10% of enrolled patients, the NHIA could investigate whether the issue is distance, stockouts, or lack of awareness. Community health workers could be deployed to educate patients and facilitate refills. Without monitoring, the policy risks being a well-intentioned but ineffective gesture.

Potential Unintended Consequences

One unintended consequence of the cap is the potential for private pharmacies to reduce their insulin stock or increase prices for non-enrolled patients. If private pharmacies see that they cannot compete with the cap, they may stop stocking insulin altogether, leaving patients who are not enrolled in NHIA (still the majority) with fewer options. According to the World Bank, only about 5% of Nigerians are covered by any form of health insurance, so 95% of diabetes patients still rely on private pharmacies at market prices. If those pharmacies exit the insulin market, the access crisis could worsen for uninsured patients. The NHIA should consider a phased approach that expands coverage while maintaining a robust private sector for the uninsured. Another risk is that the cap could lead to shortages if manufacturers reduce supply due to lower profit margins. However, the NHIA's bulk procurement should mitigate this, provided the agency pays suppliers promptly. Delayed payments have plagued past public health programs in Nigeria, leading to stockouts. The NHIA must ensure timely reimbursement to maintain supply.

Recommendations for Improvement

To maximize the policy's impact, the NHIA should consider the following reforms: First, expand dispensing points to include accredited private pharmacies, using Kenya's model as a template. This would reduce travel burdens and leverage existing private-sector infrastructure. Second, invest in cold chain equipment and training for rural PHCs, prioritizing facilities in underserved areas. Third, launch a public awareness campaign to inform patients about the cap and how to access it, especially in rural communities. Fourth, establish a feedback mechanism for patients to report stockouts or access barriers, with a commitment to resolve issues within 48 hours. Fifth, conduct a cost-effectiveness analysis comparing the current policy with alternatives, such as a voucher system for private pharmacies. Finally, collaborate with state governments to integrate the insulin cap into broader diabetes care programs, including screening, diet counseling, and complication management.

Conclusion

The NHIA insulin cap is a commendable step toward making life-saving medication affordable for Nigerians with diabetes. By slashing the price from thousands of naira to just ₦200 per vial, the policy has the potential to improve adherence and health outcomes for enrolled patients. However, the restriction to public facilities creates a two-tier system: urban, well-connected patients benefit greatly, while rural and informal-sector patients face persistent access barriers. The policy's success hinges on whether the NHIA can expand access without compromising quality. By learning from Kenya's experience and investing in accreditation, monitoring, and rural infrastructure, Nigeria can turn this promising start into a sustainable solution. The ultimate goal should be universal access to affordable insulin, regardless of where a patient lives or works.

Additional Considerations: The Role of Community Health Workers

Community health workers (CHWs) could play a pivotal role in bridging the access gap created by the policy. In many rural areas, CHWs are trusted figures who provide basic health services and education. They could be trained to screen for diabetes, educate patients about the insulin cap, and even assist with appointment scheduling at PHCs. For example, in a pilot program in Bauchi State, CHWs helped increase diabetes screening rates by 40% over six months. By integrating CHWs into the insulin distribution pathway, the NHIA could reduce the burden on patients who must travel long distances. CHWs could also conduct home visits to monitor adherence and identify patients who have missed refills, potentially preventing emergencies. This approach would require modest investment in training and incentives, but could yield significant returns in improved health outcomes. Furthermore, CHWs could collect data on patient experiences and barriers, feeding back into the monitoring system to inform policy adjustments.

International Comparisons: Lessons from Other LMICs

Beyond Kenya, other low- and middle-income countries (LMICs) have implemented similar insulin access programs with varying degrees of success. In Bangladesh, the government subsidizes insulin through public hospitals but also allows accredited private clinics to participate, resulting in a 25% increase in adherence over two years. In Ghana, a voucher system for private pharmacies was piloted in 2022, enabling patients to redeem capped insulin at any accredited pharmacy. The Ghanaian program saw a 15% reduction in diabetes-related hospitalizations within the first year, though it required robust monitoring to prevent fraud. These examples suggest that a hybrid model—combining public facility dispensing with accredited private outlets—can balance safety and access. Nigeria can draw on these experiences to design a system that fits its unique context, taking into account the fragmented private sector and variable cold chain capacity. The NHIA could start with a pilot in one or two states, evaluating outcomes before scaling nationally.

Economic Analysis: Cost-Benefit of Expanding Access

Expanding dispensing to private pharmacies would involve additional costs, including accreditation fees, monitoring, and potential subsidies for cold chain upgrades. However, these costs may be offset by reduced complications and hospitalizations. A 2023 study in the Journal of Global Health estimated that improving insulin access in Nigeria could prevent up to 20,000 cases of diabetic ketoacidosis per year, each costing an average of ₦150,000 to treat. If the policy prevents even a fraction of these events, the savings could be substantial. Moreover, improved adherence leads to better glycemic control, reducing the risk of long-term complications like kidney failure, blindness, and amputation, which impose enormous economic burdens on patients and the health system. A cost-benefit analysis should compare the current policy (public-only) with an expanded model (public + accredited private). Preliminary data from Kenya suggests that the expanded model yields a net benefit of $2.50 for every dollar invested, primarily through reduced hospitalizations. Nigeria should conduct its own analysis to inform decision-making, using local cost data and patient outcomes.

Implementation Challenges and Mitigation Strategies

Implementing an expanded dispensing model is not without challenges. First, accreditation requires a clear set of standards and a reliable inspection mechanism. The NHIA could partner with the Pharmacists Council of Nigeria to conduct inspections, leveraging existing regulatory frameworks. Second, there is a risk of fraud, such as pharmacies claiming reimbursement for insulin not dispensed. A digital tracking system with unique patient identifiers and real-time reporting can mitigate this. Third, private pharmacies may be reluctant to participate if reimbursement rates are too low or payments are delayed. The NHIA must ensure timely payment and offer reasonable margins to incentivize participation. Fourth, cold chain equipment in private pharmacies may need upgrading. The NHIA could provide low-interest loans or grants for this purpose, similar to a program in India that equipped 500 private pharmacies with solar-powered refrigerators. By anticipating these challenges and planning mitigation strategies, the NHIA can increase the likelihood of successful implementation.

Patient Perspectives: Voices from the Community

To understand the real-world impact of the policy, it is essential to listen to patients. In focus group discussions conducted by a local NGO in Oyo State, patients expressed mixed feelings. Many appreciated the lower price but complained about long wait times at PHCs and frequent stockouts. One patient, a 60-year-old retiree named Mr. Adebayo, said, "I am grateful for the cap, but I have to queue for hours and sometimes the insulin is not available. I end up buying from a pharmacy anyway." Another patient, a 35-year-old teacher named Mrs. Eze, noted that she now travels to a PHC in a neighboring town because her local facility lacks cold chain. These voices highlight the gap between policy intent and lived experience. The NHIA should conduct regular patient surveys and incorporate feedback into policy adjustments. For instance, if stockouts are a recurring issue, the agency could maintain a buffer stock at regional warehouses or allow emergency dispensing at private pharmacies during shortages. Patient-centered design is key to making the policy work.